{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T22:05:55Z","timestamp":1790805955264,"version":"4.1.0"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,11]],"date-time":"2025-03-11T00:00:00Z","timestamp":1741651200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100013669","name":"Ionis Pharmaceuticals Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013669","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004628","name":"MedImmune","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004628","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100020431","name":"Funda\u00e7\u00e3o Lemann","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100020431","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005565","name":"Johnson & Johnson Innovative Medicine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005565","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Heart Journal"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.ahj.2025.03.003","type":"journal-article","created":{"date-parts":[[2025,3,8]],"date-time":"2025-03-08T19:36:36Z","timestamp":1741462596000},"page":"125-135","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Design and rationale of the CORE-TIMI\u202f72a and CORE2-TIMI\u202f72b trials of olezarsen in patients with severe hypertriglyceridemia"],"prefix":"10.1016","volume":"286","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1339-8076","authenticated-orcid":false,"given":"Nicholas A.","family":"Marston","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian A.","family":"Bergmark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronica J.","family":"Alexander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ewa","family":"Karwatowska-Prokopczuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu Mi","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filipe A.","family":"Moura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas A.","family":"Prohaska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andre","family":"Zimerman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuanglu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabina A.","family":"Murphy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sotirios","family":"Tsimikas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert P.","family":"Giugliano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc S.","family":"Sabatine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.ahj.2025.03.003_bib0001","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/j.amjcard.2010.11.008","article-title":"Prevalence of severe (500 to 2,000 mg\/dl) hypertriglyceridemia in United States adults","volume":"107","author":"Christian","year":"2011","journal-title":"Am J Cardiol"},{"issue":"39","key":"10.1016\/j.ahj.2025.03.003_bib0002","doi-asserted-by":"crossref","first-page":"2999","DOI":"10.1093\/eurheartj\/ehw272","article-title":"2016 ESC\/EAS Guidelines for the management of dyslipidaemias","volume":"37","author":"Catapano","year":"2016","journal-title":"Eur Heart J"},{"issue":"8","key":"10.1016\/j.ahj.2025.03.003_bib0003","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1503\/cmaj.060963","article-title":"Hypertriglyceridemia: its etiology, effects and treatment","volume":"176","author":"Yuan","year":"2007","journal-title":"CMAJ"},{"key":"10.1016\/j.ahj.2025.03.003_bib0004","article-title":"New approaches to triglyceride reduction: is there any hope left?","volume":"18","author":"Filtz","year":"2024","journal-title":"Am J Prev Cardiol"},{"issue":"3","key":"10.1016\/j.ahj.2025.03.003_bib0005","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.ecl.2022.02.010","article-title":"Hypertriglyceridemia","volume":"51","author":"Chait","year":"2022","journal-title":"Endocrinol Metab Clin North Am"},{"issue":"8","key":"10.1016\/j.ahj.2025.03.003_bib0006","doi-asserted-by":"crossref","first-page":"2855","DOI":"10.1172\/JCI86610","article-title":"ApoC-III inhibits clearance of triglyceride-rich lipoproteins through LDL family receptors","volume":"126","author":"Gordts","year":"2016","journal-title":"J Clin Invest"},{"issue":"18","key":"10.1016\/j.ahj.2025.03.003_bib0007","doi-asserted-by":"crossref","first-page":"2843","DOI":"10.1093\/cvr\/cvad177","article-title":"Exploring apolipoprotein C-III: pathophysiological and pharmacological relevance","volume":"119","author":"Packard","year":"2024","journal-title":"Cardiovasc Res"},{"issue":"5","key":"10.1016\/j.ahj.2025.03.003_bib0008","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/S2213-8587(21)00046-2","article-title":"Efficacy and safety of volanesorsen in patients with multifactorial chylomicronaemia (COMPASS): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial","volume":"9","author":"Gouni-Berthold","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"6","key":"10.1016\/j.ahj.2025.03.003_bib0009","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1056\/NEJMoa1715944","article-title":"Volanesorsen and triglyceride levels in familial chylomicronemia syndrome","volume":"381","author":"Witztum","year":"2019","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.ahj.2025.03.003_bib0010","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1089\/nat.2016.0623","article-title":"Disposition and pharmacokinetics of a GalNAc3-conjugated antisense oligonucleotide targeting Human lipoprotein (a) in monkeys","volume":"26","author":"Yu","year":"2016","journal-title":"Nucleic Acid Ther"},{"issue":"19","key":"10.1016\/j.ahj.2025.03.003_bib0011","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1056\/NEJMoa2402309","article-title":"Olezarsen for hypertriglyceridemia in patients at high cardiovascular risk","volume":"390","author":"Bergmark","year":"2024","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.ahj.2025.03.003_bib0012","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1056\/NEJMoa2400201","article-title":"Olezarsen, acute pancreatitis, and familial chylomicronemia syndrome","volume":"390","author":"Stroes","year":"2024","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.ahj.2025.03.003_bib0013","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1056\/NEJMoa1400283","article-title":"Antisense inhibition of apolipoprotein C-III in patients with hypertriglyceridemia","volume":"373","author":"Gaudet","year":"2015","journal-title":"N Engl J Med"},{"issue":"14","key":"10.1016\/j.ahj.2025.03.003_bib0014","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1093\/eurheartj\/ehab820","article-title":"Apolipoprotein C-III reduction in subjects with moderate hypertriglyceridaemia and at high cardiovascular risk","volume":"43","author":"Tardif","year":"2022","journal-title":"Eur Heart J"},{"issue":"1","key":"10.1016\/j.ahj.2025.03.003_bib0015","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1136\/gutjnl-2012-302779","article-title":"Classification of acute pancreatitis\u20132012: revision of the Atlanta classification and definitions by international consensus","volume":"62","author":"Banks","year":"2013","journal-title":"Gut"},{"issue":"9","key":"10.1016\/j.ahj.2025.03.003_bib0016","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1161\/CIRCULATIONAHA.117.033502","article-title":"2017 Cardiovascular and stroke endpoint definitions for clinical trials","volume":"137","author":"Hicks","year":"2018","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.ahj.2025.03.003_bib0017","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.jacl.2023.04.007","article-title":"APOC3 inhibition with volanesorsen reduces hepatic steatosis in patients with severe hypertriglyceridemia","volume":"17","author":"Prohaska","year":"2023","journal-title":"J Clin Lipidol"},{"issue":"10","key":"10.1016\/j.ahj.2025.03.003_bib0018","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1056\/NEJMoa2404143","article-title":"Plozasiran, an RNA interference agent targeting APOC3, for mixed hyperlipidemia","volume":"391","author":"Ballantyne","year":"2024","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.ahj.2025.03.003_bib0019","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1001\/jamacardio.2024.0959","article-title":"Plozasiran (ARO-APOC3) for severe hypertriglyceridemia: the SHASTA-2 randomized clinical trial","volume":"9","author":"Gaudet","year":"2024","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.ahj.2025.03.003_bib0020","article-title":"Plozasiran for managing persistent chylomicronemia and pancreatitis risk","author":"Watts","year":"2024","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.ahj.2025.03.003_bib0021","doi-asserted-by":"crossref","first-page":"e261","DOI":"10.1016\/j.jacl.2023.12.001","article-title":"Hepatic fat changes with antisense oligonucleotide therapy targeting ANGPTL3","volume":"18","author":"Zimerman","year":"2024","journal-title":"J Clin Lipidol"},{"issue":"6","key":"10.1016\/j.ahj.2025.03.003_bib0022","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.jacl.2022.08.008","article-title":"Assessment of efficacy and safety of volanesorsen for treatment of metabolic complications in patients with familial partial lipodystrophy: results of the BROADEN study: Volanesorsen in FPLD; the BROADEN Study","volume":"16","author":"Oral","year":"2022","journal-title":"J Clin Lipidol"},{"issue":"4","key":"10.1016\/j.ahj.2025.03.003_bib0024","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.cmet.2018.03.004","article-title":"RNA-targeted Therapeutics","volume":"27","author":"Crooke","year":"2018","journal-title":"Cell Metab"},{"issue":"1","key":"10.1016\/j.ahj.2025.03.003_bib0025","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1186\/s12944-024-02297-5","article-title":"Efficacy and safety of olezarsen in lowering apolipoprotein C-III and triglycerides in healthy Japanese Americans","volume":"23","author":"Karwatowska-Prokopczuk","year":"2024","journal-title":"Lipids Health Dis"},{"issue":"Supplement_1","key":"10.1016\/j.ahj.2025.03.003_bib0026","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/ehae666.2872","article-title":"Rationale and design of the SHASTA-3 and SHASTA-4 studies: randomized, double-blind, placebo-controlled, phase 3 studies of plozasiran in patients with severe hypertriglyceridemia","volume":"45","author":"Gaudet","year":"2024","journal-title":"European Heart Journal"}],"container-title":["American Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870325000730?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870325000730?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T09:16:57Z","timestamp":1746523017000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002870325000730"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":25,"alternative-id":["S0002870325000730"],"URL":"https:\/\/doi.org\/10.1016\/j.ahj.2025.03.003","relation":{},"ISSN":["0002-8703"],"issn-type":[{"value":"0002-8703","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Design and rationale of the CORE-TIMI\u202f72a and CORE2-TIMI\u202f72b trials of olezarsen in patients with severe hypertriglyceridemia","name":"articletitle","label":"Article Title"},{"value":"American Heart Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ahj.2025.03.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.ahj.2025.02.022","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}